
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc. has demonstrated strong financial performance, with management reporting that its Integrity product achieved sequential revenue growth and is projected to exhibit over 100% growth from 2024 to 2025. Additionally, the company experienced a significant increase in international osteoarthritis (OA) pain revenue, rising by 21% year-over-year, further enhancing its growth trajectory. The regenerative solutions business also performed well, showing an impressive 41% growth in the quarter, underscoring the company's commitment to innovative therapies in the orthopedic space.
Bears say
Anika Therapeutics Inc reported a revenue decline of 5.9% to $27.8 million, reflecting ongoing challenges in its revenue generation, with previous reports indicating an 8.2% decrease compared to the prior year, highlighting a consistent downward trend. The company's disappointing gross margin of 56%, falling short of the estimated 58%, is attributed to production yield issues that have persisted, further straining its financial performance. Additionally, international revenue from osteoarthritis pain management saw a significant 10% decline, exacerbating concerns over order timing and recurring production problems which contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares